加载中
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
前收盘价
US$23.53
+US$0.71 · +3.11%
盘中时间采用ET。市场数据可能有所延迟。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日内区间
当前US$23.53
52周区间
当前US$23.53
盘中时间采用ET。市场数据可能有所延迟。
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
日内区间
当前US$23.53
52周区间
当前US$23.53
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7230.3万 USD | 2852万 USD | 716.3万 USD | — | 625.4万 USD |
| 销货成本 | 12.9万 USD | 5593.3万 USD | 4890万 USD | 6908万 USD | — |
| 毛利 | 7217.4万 USD | −2741.3万 USD | −4173.7万 USD | −6908万 USD | 625.4万 USD |
| 研究与开发 | 6481.3万 USD | 5593.3万 USD | 4890万 USD | 6998万 USD | 6852.4万 USD |
| 销售、一般及管理费用 | 1960.8万 USD | 1800.7万 USD | 2290.9万 USD | 2393.4万 USD | 2878万 USD |
| 营业费用 | 8442.1万 USD | 1800.7万 USD | 2290.9万 USD | 2503.4万 USD | 1.39亿 USD |
| 利息收入 | 599.6万 USD | 557.3万 USD | 345.1万 USD | 102.2万 USD | 30.2万 USD |
| 折旧和摊销 | 12.9万 USD | 12.9万 USD | 45万 USD | 49.8万 USD | 46.6万 USD |
| 营业利润 | −1211.8万 USD | −4542万 USD | −6464.6万 USD | −9411.4万 USD | −1.33亿 USD |
| 净利润 | −612.2万 USD | −4017.7万 USD | −6122.8万 USD | −9309.2万 USD | −1.3亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$51.67
上涨空间 119.59%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年2月12日 | 1:12 | — | — |
股票拆分 | 2014年7月14日 | 1:5 | — | — |
已生效 2024年2月12日
1:12
已生效 2014年7月14日
1:5
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1389.87万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM790.49万0.01%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI697.86万0.07%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF443.53万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO190.15万0.01%180亿 USD0.06%US$112.66+0.50%
Vanguard Health Care ETFVHT112.38万0.01%220亿 USD0.09%US$319.01+1.64%
iShares Micro-Cap ETFIWC96.73万0.07%13.17亿 USD0.60%US$183+0.11%
Fidelity Enhanced Small Cap ETFFESM52.02万0.01%64.1亿 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
